Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers
Jia Li, Muhammad Wasif SaifYale Cancer Center, Yale School of Medicine, New Haven CT, USAAbstract: Angiogenesis is essential for cancer growth and metastasis. Vascular endothelial growth factor (VEGF) is a key modulator of angiogenesis. In addition, overexpression of VEGF is correlated with advanced...
Guardado en:
Autores principales: | Jia Li, Muhammad Wasif Saif |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4d99a45cd9d247f0b2e0be29ea4bccc8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Bevacizumab in the treatment of ovarian cancer
por: Ramez N Eskander, et al.
Publicado: (2011) -
Bevacizumab in the treatment of HER2-negative breast cancer
por: Vito Lorusso
Publicado: (2008) -
Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
por: Richard Quek, et al.
Publicado: (2010) -
Bevacizumab in the therapy for refractory metastatic colorectal cancer
por: Mary F Mulcahy
Publicado: (2008) -
Targeted therapies in the management of renal cell carcinoma: role of bevacizumab
por: Bernard Escudier, et al.
Publicado: (2008)